MedTrace Logo

HRR Prevalence in LatAm PROSPECT Study

NCT04962880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 388

Last updated 2023-04-14

No results posted yet for this study

Summary

Determine the prevalence of homologous recombination repair (HRR) gene mutations in participants with mCRPC in Latin America (LatAm) between February 2021 and January 2022.

Conditions

  • Castration-resistant Prostate Cancer

Sponsors & Collaborators

Principal Investigators

  • Gabriel Garbaos, MD · Fundación Estudios Clinicos

  • Martin Angel, MD · INSTITUTO ALEXANDER FLEMING

  • Ray Manneh Kopp, MD · Sociedad de Oncología y Hematología del Cesar S.A.S.

  • Jorge A Chaves Porras, MD · Instituto de Investigaciones en Ciencias Médicas (ICIMED)

  • Alejandro Crismatt, MD · Centro Hemato Oncológico Panamá (CHOP)

  • Silvia Neciosup, MD · Centro de Investigación Oncosalud - RCI N° 166

  • Miguel A Álvarez Avitia, MD · Instituto Nacional de Cancerología (INCAN)

  • Arturo Delgado Herrera, MD · Centro Médico Nacional Siglo XXI (CMNSXXI)

  • Pedro H Isaacsson Velho, MD · Centro de Pesquisa Hospital Moinhos de Vento

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-21
Primary Completion
2022-04-08
Completion
2022-04-08

Countries

  • Argentina
  • Brazil
  • Colombia
  • Costa Rica
  • Mexico
  • Panama
  • Peru

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04962880 on ClinicalTrials.gov